These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33306184)

  • 21. Assessment of the comparability of CLSI, EUCAST and Stokes antimicrobial susceptibility profiles for Escherichia coli uropathogenic isolates.
    O'Halloran C; Walsh N; O'Grady MC; Barry L; Hooton C; Corcoran GD; Lucey B
    Br J Biomed Sci; 2018 Jan; 75(1):24-29. PubMed ID: 29210602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children.
    Calzi A; Grignolo S; Caviglia I; Calevo MG; Losurdo G; Piaggio G; Bandettini R; Castagnola E
    Eur J Pediatr; 2016 Sep; 175(9):1219-1225. PubMed ID: 27558493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of urine concentrations of amoxicillin and clavulanate in cats.
    KuKanich K; Woodruff K; Bieberly Z; Papich MG; KuKanich B
    J Vet Intern Med; 2021 Jan; 35(1):456-461. PubMed ID: 33280171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
    Doern GV; Brueggemann AB; Pierce G; Holley HP; Rauch A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):292-7. PubMed ID: 9021182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections.
    Vazouras K; Velali K; Tassiou I; Anastasiou-Katsiardani A; Athanasopoulou K; Barbouni A; Jackson C; Folgori L; Zaoutis T; Basmaci R; Hsia Y
    J Glob Antimicrob Resist; 2020 Mar; 20():4-10. PubMed ID: 31252156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Ukraine and the Slovak Republic.
    Torumkuney D; Pertseva T; Bratus E; Dziublik A; Yachnyk V; Liskova A; Sopko O; Malynovska K; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v28-v35. PubMed ID: 29659885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
    Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
    Clin Infect Dis; 2024 Aug; 79(2):516-523. PubMed ID: 38626241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in the Czech Republic.
    Torumkuney D; Zemlickova H; Maruscak M; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v22-v27. PubMed ID: 29659883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the effectiveness of three different cephalosporin/clavulanate combinations for the phenotypic confirmation of extended-spectrum beta-lactamase producing bacteria isolated from urine samples at National Public Health Laboratory, Kathmandu, Nepal.
    Bhandari R; Pant ND; Poudel A; Sharma M
    BMC Res Notes; 2016 Aug; 9():390. PubMed ID: 27488224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
    Simpson I; Durodie J; Knott S; Shea B; Wilson J; Machka K
    J Clin Microbiol; 1998 May; 36(5):1361-5. PubMed ID: 9574706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis.
    McAdoo MA; Rice K; Gordon GR; Sahn SA
    Clin Ther; 1998; 20(1):88-100. PubMed ID: 9522107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Extended-spectrum beta-lactamase production by Enterobacteriaceae isolates from urine cultures of outpatients: results of a 7-year follow-up].
    Çelikbilek N; Gözalan A; Özdem B; Kırca F; Açıkgöz ZC
    Mikrobiyol Bul; 2015 Apr; 49(2):259-65. PubMed ID: 26167826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.